Does treatment sequence affect outcomes in patients with metaplastic breast cancer? - 12/04/21

Doi : 10.1016/j.amjsurg.2021.01.007

Oluwatomi L. Ladipo ^a, Yi Ren ^b, Keenan B. Caddell ^a, Anuyuga Sampathkumar ^a, Chandra A. Almond ^a, Oluwadamilola M. Fayanju ^a,^c,^d,^e,^f,^⁎
^a Department of Surgery, Duke University Medical Center, Box 3513, Durham, NC, 27710, USA
^b Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, 27710, USA
^c Women’s Cancer Program, Duke Cancer Institute, Durham, NC, 27710, USA
^d Department of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, Durham, NC, 27701, USA
^e Duke Forge, Duke University, Durham, NC, 27710, USA
^f Department of Surgery, Durham VA Medical Center, 508 Fulton St, Durham, NC, 27705, USA

^∗Corresponding author. Department of Surgery, DUMC 3513, Durham, NC, 27710, USA.Department of SurgeryDUMC 3513DurhamNC27710USA

Abstract

Introduction

We compared characteristics and outcomes by treatment sequence among patients with metaplastic breast cancer (MBC), an aggressive subtype.

Methods

Women ≥18 years old with newly diagnosed Stage I-III MBC from 2003 to 2018 who received any treatment in our health system were identified. Unadjusted overall survival (OS) was estimated with the Kaplan-Meier method; the log-rank test was used to compare survival differences between recipients of neoadjuvant (NACT) and adjuvant chemotherapy (ACT).

Results

Of the 91 MBC patients identified, 60 received chemotherapy. NACT recipients (n = 20, median age 46.5 y) were younger than ACT recipients (n = 40, median age 60.5 y, p < 0.001) but similar with regards to race and radiation receipt. There was no significant OS difference between NACT and ACT recipients (log-rank p = 0.15), which remained true when patients were stratified by age (≥50 y vs < 50 y).

Conclusions

Among MBC patients, NACT recipients were younger than ACT recipients, but there was no survival difference by treatment sequence.

Le texte complet de cet article est disponible en PDF.

Highlights

•	In our study of metaplastic breast cancer (MBC), an aggressive subtype:
•	Most MBC patients received neoadjuvant (NACT) or adjuvant chemotherapy (ACT).
•	NACT recipients were younger than ACT recipients.
•	NACT and ACT recipients were similar with regards to race and radiation receipt.
•	MBC patients had similar survival regardless of treatment sequence.

Le texte complet de cet article est disponible en PDF.

Keywords : Breast cancer, Metaplastic, Chemotherapy, Adjuvant, Neoadjuvant, Treatment sequence

Plan

Introduction

Materials and methods

Export

Vol 221 - N° 4

P. 701-705 - avril 2021 Retour au numéro

Article précédent

Do male chairs of surgery have implicit gender bias in the residency application process?
Sophie Dream, Meagan Mandabach Olivet, Lauren Tanner, Herbert Chen

| Article suivant

Does acral lentiginous melanoma subtype account for differences in patterns of care in Black patients?
Taylor M. Carter, Paula D. Strassle, David W. Ollila, Karyn B. Stitzenberg, Michael O. Meyers, Ugwuji N. Maduekwe

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Does treatment sequence affect outcomes in patients with metaplastic breast cancer? - 12/04/21

Abstract

Introduction

Methods

Results

Conclusions

Highlights

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL